اكتشف أفضل عيادات وتكاليف العلاج فحص توافق مستضد كريات الدم البيضاء البشرية HLA-typing في أنقرة 2024

Prof. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023. His medical interests include: Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic) Acute Leukemia Chronic Leukemia Treatments Hodgkin Lymphoma Non-Hodgkin Lymphoma Treatments Multiple Myeloma Treatments, MDS Aplastic Anemia ITP TTP Treatments Hypercoagulability Hereditary Thrombophilia Treatments Therapeutic Apheresis Photopheresis Geriatric Hematology Diseases.

BRIEF SUMMARYOF WORK EXPERIENCE  Including those I had transplanted during my fellowship at RUSH University in Chicago (n=86), I have performed a total of 705 liver transplants (%94 adult) both from living (%75) and cadaveric (%25) donors. And, additionally 340 kidney transplants which were mostly from living donors, too. Of these, 12 were combined liver and kidney transplantations either from cadaveric or living donors. Currently, I am the Director of Organ Transplant Program at GUVEN Hospital in Ankara. As of March 2018, here in GUVEN Hospital, we have performed 145 liver transplants (118 from living donors) with 1, 3 and 5 years patient survival of 91.2%, 86%and 83%, consecutively(ELTR data analysis). Since 1997, besides organ transplantation, I have also been operating on complicated hepato-pancreato-biliary patients